Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

BACKGROUND: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are importa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Leiter, Lawrence A., Bain, Stephen C., Hramiak, Irene, Jódar, Esteban, Madsbad, Sten, Gondolf, Theis, Hansen, Thomas, Holst, Ingrid, Lingvay, Ildiko
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551895/
https://ncbi.nlm.nih.gov/pubmed/31167654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0871-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars